Regulus Therapeutics Inc.
RGLS
$2.06
$0.126.19%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -54.34% | -44.69% | -24.18% | -9.13% | -6.05% |
| Total Depreciation and Amortization | 52.86% | 82.61% | 88.75% | 80.56% | 86.07% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 123.34% | 149.44% | 190.83% | 140.96% | 31.06% |
| Change in Net Operating Assets | -832.30% | 148.67% | -306.17% | 224.24% | -53.27% |
| Cash from Operations | -55.68% | -33.67% | -19.85% | -0.50% | -4.87% |
| Capital Expenditure | 44.54% | 32.07% | -1,279.10% | -223.46% | -69.81% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -336.03% | -364.86% | -717.22% | -32,553.94% | 202.32% |
| Cash from Investing | -348.31% | -374.90% | -727.81% | -415,963.16% | 195.84% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 58.32% | 11.10% | -83.35% | -300.00% | -- |
| Issuance of Common Stock | 519.77% | 519.35% | 412.56% | 2,318.56% | 237.72% |
| Repurchase of Common Stock | -57.45% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 682.13% | 621.44% | 443.34% | 2,769.87% | 163.10% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3,301.95% | -90.72% | -1,039.41% | 96.94% | 98.72% |